A phase III randomized trial of BAY 12-9566 (tanomastat) as maintenance therapy in patients with advanced ovarian cancer responsive to primary surgery and paclitaxel/platinum containing chemotherapy: a National Cancer Institute of Canada Clinical Tr
about
Maintenance bioimmunotherapy for epithelial ovarian cancerMaintenance Therapy in Ovarian Cancer with Targeted Agents Improves PFS and OS: A Systematic Review and Meta-AnalysisCandidate prognostic markers in breast cancer: focus on extracellular proteases and their inhibitorsCell-cell and cell-matrix dynamics in intraperitoneal cancer metastasisTumor stroma as targets for cancer therapyAnti-tumour effects of a specific anti-ADAM17 antibody in an ovarian cancer model in vivoExtracellular matrix molecules: potential targets in pharmacotherapy.Recommended patient-reported core set of symptoms and quality-of-life domains to measure in ovarian cancer treatment trials.Cancer associated fibroblasts (CAFs) in tumor microenvironment.Current status of maintenance therapy for advanced ovarian cancer.Targeting Matrix Metalloproteinases in Cancer: Bringing New Life to Old IdeasContemporary quality of life issues affecting gynecologic cancer survivors.The Globalization of Cooperative Groups.Proteinases in the joint: clinical relevance of proteinases in joint destructionDevelopment of musculoskeletal toxicity without clear benefit after administration of PG-116800, a matrix metalloproteinase inhibitor, to patients with knee osteoarthritis: a randomized, 12-month, double-blind, placebo-controlled study.Estimation of expectedness: predictive accuracy of standard therapy outcomes in randomized phase 3 studies in epithelial ovarian cancer.MT1-MMP is the critical determinant of matrix degradation and invasion by ovarian cancer cells.Investigational agents against platinum-resistant ovarian cancer.Continued chemotherapy after complete response to primary therapy among women with advanced ovarian cancer: a meta-analysisMatrix metalloproteinase-10 regulates stemness of ovarian cancer stem-like cells by activation of canonical Wnt signaling and can be a target of chemotherapy-resistant ovarian cancer.Effect of interleukin-8 gene silencing with liposome-encapsulated small interfering RNA on ovarian cancer cell growth.Stromal Modulators of TGF-β in Cancer.Anti-angiogenic drug discovery: lessons from the past and thoughts for the future.Pharmacodynamic considerations in the use of matrix metalloproteinase inhibitors in cancer treatment.Matrix metalloproteinases: their functional role in lung cancer.A Systematic Review of Health-Related Quality of Life Reporting in Ovarian Cancer Phase III Clinical Trials: Room to Improve.Emerging enzymatic targets controlling angiogenesis in cancer: preclinical evidence and potential clinical applications.Strategies to Target Matrix Metalloproteinases as Therapeutic Approach in Cancer.Overall survival and post-progression survival are potent endpoint in phase III trials of second/third-line chemotherapy for advanced or recurrent epithelial ovarian cancer.Fluctuating roles of matrix metalloproteinase-9 in oral squamous cell carcinoma
P2860
Q24234761-7C48A249-8DB6-43F7-990D-A585510DD3EAQ26781561-F5D34161-391F-43A0-886C-21D8D798A420Q26830522-A1484BC7-344E-4045-8F5C-BF0D73EE7E1DQ26851836-3AEF0C85-9519-4328-BC95-A7213EF573DBQ27015980-C53AE911-F0AF-4ED2-B59B-05BAC8E390EBQ28727262-D160ADE8-D63D-47CF-ACB7-E826480A1241Q33694487-0AF533B8-1921-4B9A-88AA-CB38B0F6511EQ33947886-A0614A97-37C0-421D-A558-BCF5B9FC7FA4Q33999773-ED836123-8BDB-4095-8195-461D154E2AF5Q34271924-2A4BFFA2-FF29-4F57-994F-49F0215BCE8BQ35760031-2DBF6975-E475-4A6A-B8A4-86D0F4549BF2Q36067725-0F5F8C11-E443-4D6C-8285-0CCD74DCF13FQ36119749-B8179542-D604-4C50-BCD0-744340250B81Q36401848-76B92270-22BC-43C2-9FCD-835ED6904C26Q36401915-F439BA1D-2684-40A4-A56A-4F0F3F7A59A7Q36584405-325E5359-C838-40B5-B067-F0EF33B7316CQ36610951-D48CDF5A-41F4-49DC-902F-3890970A9E8CQ36736349-18FF8F94-4937-4E8B-BD70-70D9A6CC9273Q37086928-F511F4F8-978D-4A0C-96DA-5CE1D2424083Q37295807-5753585E-51D4-4681-A46E-FE575BF800B3Q37405207-525DC631-D275-4EDC-8F84-3EF1C805464EQ37628179-1479ACC9-F874-4F79-9C72-442430B2D03BQ38020234-036CA1BE-D46D-4966-AB00-B96C5E59B94EQ38725320-BCB002AB-3EE2-449A-9A1D-D72730175346Q39388493-F996A39B-DD10-4B44-A4C8-7852E2AE4773Q47629735-134F15DB-1CC9-4D05-8D58-7B69DA361CA6Q48171089-9D39ADC9-0D85-4A76-BE42-8F874322391EQ50109651-F80B9474-6F90-4890-8540-BFF018B29528Q54951150-D903E763-D960-40A3-A81C-A4A974C61322Q59034785-412A8020-EEF1-4A0D-8E60-5A359145F697
P2860
A phase III randomized trial of BAY 12-9566 (tanomastat) as maintenance therapy in patients with advanced ovarian cancer responsive to primary surgery and paclitaxel/platinum containing chemotherapy: a National Cancer Institute of Canada Clinical Tr
description
2006 nî lūn-bûn
@nan
2006 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
A phase III randomized trial o ...... nstitute of Canada Clinical Tr
@ast
A phase III randomized trial o ...... nstitute of Canada Clinical Tr
@en
type
label
A phase III randomized trial o ...... nstitute of Canada Clinical Tr
@ast
A phase III randomized trial o ...... nstitute of Canada Clinical Tr
@en
prefLabel
A phase III randomized trial o ...... nstitute of Canada Clinical Tr
@ast
A phase III randomized trial o ...... nstitute of Canada Clinical Tr
@en
P2093
P921
P1433
P1476
A phase III randomized trial o ...... da Clinical Trials Group Study
@en
P2093
I B Vergote
J R Jeffrey
M Brundage
R N Grimshaw
S Coppieters
P304
P356
10.1016/J.YGYNO.2005.12.020
P407
P577
2006-01-25T00:00:00Z